MOMETASONE FUROATE

Search structure
Trade Names:
Synonyms:
Status: Approved (1987)
Entry Type: Small molecule
Molecule Category: Parent Prodrug
UNII: 04201GDN4R
Parent Compound: MOMETASONE

Structure
InChI Key WOFMFGQZHJDGCX-ZULDAHANSA-N
Smile C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl
InChI
InChI=1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C27H30Cl2O6
Molecular Weight 521.44
AlogP 4.87
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 4.0
Polar Surface Area 93.81
Molecular species NEUTRAL
Aromatic Rings 1.0
Heavy Atoms 35.0

Pharmacology

Action Mechanism of Action Reference
AGONIST Glucocorticoid receptor agonist
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Hydrolase
- - - -
Enzyme Transferase
- - - - 1.363
Epigenetic regulator Eraser Histone deacetylase HDAC class IIb
- - - - -2.71-7.54
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 1
- - - 0.7 -
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 3
- - 0.08 - -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- 1148.15 - 1620 25.64

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Nasal Polyps 4 D009298 ClinicalTrials
Rhinitis, Allergic, Perennial 3 D012221 ClinicalTrials
Hypertrophy 3 D006984 ClinicalTrials
Pulmonary Disease, Chronic Obstructive 3 D029424 ClinicalTrials
Sleep Apnea, Obstructive 3 D020181 ClinicalTrials
Sinusitis 3 D012852 ClinicalTrials
Breast Neoplasms 3 D001943 ClinicalTrials
Severe Acute Respiratory Syndrome 3 D045169 ClinicalTrials
Psoriasis 2 D011565 ClinicalTrials
Radiodermatitis 2 D011855 ClinicalTrials
Pemphigoid, Bullous 2 D010391 ClinicalTrials
Psoriasis 2 D011565 ClinicalTrials
Dermatitis, Atopic 2 D003876 ClinicalTrials
Anemia, Sickle Cell 2 D000755 ClinicalTrials
Eosinophilic Esophagitis 2 D057765 ClinicalTrials
Spinal Cord Injuries 1 D013119 ClinicalTrials
Hypersensitivity 1 D006967 ClinicalTrials
Alopecia Areata 1 D000506 ClinicalTrials
Otitis Media with Effusion 1 D010034 ClinicalTrials

Related Entries

Scaffolds

Parent
Mixture

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Product issues
24.42
General disorders and administration site conditions
21.33
Injury, poisoning and procedural complications
14.68
Respiratory, thoracic and mediastinal disorders
12.26
Cardiac disorders
4.3
Nervous system disorders
3.89
Gastrointestinal disorders
2.79
Skin and subcutaneous tissue disorders
2.56
Psychiatric disorders
2.19

Cross References

Resources Reference
CAS NUMBER 83919-23-7
ChEBI 47564
ChEMBL CHEMBL1161
DrugBank DB14512
DrugCentral 1832
EPA CompTox DTXSID4023333
FDA SRS 04201GDN4R
KEGG C07817
PDB MOF
PubChem 441336
SureChEMBL SCHEMBL4568
ZINC ZINC000003938677
CONTENTS